Jazz Pharmaceuticals: cross-border access for the specialty portfolio

Quick orientation

Jazz Pharmaceuticals plc is an Irish-incorporated global biopharmaceutical company with US headquarters in Palo Alto, California. Jazz's strategic focus is on neuroscience (sleep disorders, epilepsy) and oncology (hematology, solid tumors), with a portfolio that includes both internally developed products and franchises acquired through the GW Pharmaceuticals acquisition (Epidiolex) and other transactions. Jazz trades on NASDAQ as JAZZ. FDA approval scale spans approximately ten marketed products across narcolepsy, idiopathic hypersomnia, refractory epilepsy syndromes, acute lymphoblastic leukemia, hepatic veno-occlusive disease, and other indications. The company is one of the most concentrated specialty operators in CNS rare disease.

Jazz portfolio in cross-border NPP scope

Xywav (calcium, magnesium, potassium, and sodium oxybates) is an FDA-approved low-sodium oxybate oral solution for cataplexy or excessive daytime sleepiness in narcolepsy and for idiopathic hypersomnia in adults (FDA approval July 2020 for narcolepsy; August 2021 for idiopathic hypersomnia). Twice-nightly dosing. US list pricing varies but is approximately US$12,000-$15,000 per month. Xywav is a Schedule III controlled substance in the United States and requires a Risk Evaluation and Mitigation Strategy (REMS) program for distribution. Cross-border NPP for Schedule III controlled substances is generally outside Reserve Meds' scope due to international controlled-substance regulations; we route patient inquiries appropriately and do not coordinate Schedule III shipments.

Epidiolex (cannabidiol) is an FDA-approved purified plant-derived CBD oral solution for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex in patients one year of age and older (initial FDA approval June 2018; TSC indication July 2020). US list pricing is approximately US$32,500 per year at average weight-based dosing. Epidiolex was rescheduled from Schedule V to a non-controlled status in May 2020 in the United States, which removes the controlled-substance constraint for export coordination. Reserve Meds coordinates Epidiolex through US specialty distribution.

Defitelio (defibrotide sodium) is an FDA-approved therapy for hepatic veno-occlusive disease (also known as hepatic sinusoidal obstruction syndrome) with renal or pulmonary dysfunction following hematopoietic stem cell transplantation. Rylaze (asparaginase erwinia chrysanthemi recombinant-rywn) is FDA-approved as a component of multi-agent chemotherapy regimens for acute lymphoblastic leukemia and lymphoblastic lymphoma. Sunosi (solriamfetol) is an FDA-approved wakefulness-promoting agent for excessive daytime sleepiness in narcolepsy or obstructive sleep apnea. Zepzelca (lurbinectedin) is FDA-approved for metastatic small cell lung cancer after platinum-based chemotherapy.

Why patients route through cross-border NPP

Epidiolex is the highest-volume cross-border NPP demand driver in the Jazz portfolio. Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex are rare pediatric epilepsy syndromes with substantial unmet need. Even with multiple anti-seizure medications, many patients have continued seizure burden. Epidiolex is the only FDA-approved purified pharmaceutical-grade CBD product with a defined and reproducible cannabinoid profile, and quality control is significantly different from artisanal CBD products available regionally. Outside the United States, Epidiolex is approved by EMA under the trade name Epidyolex, but commercial availability in the GCC, India, and most of MENA lags significantly. Families with confirmed diagnosis and treating-pediatric-neurologist prescription routinely seek US-sourced supply.

Defitelio for hepatic VOD post-transplant is a niche emergency-use indication where confirmed-diagnosis patients in major transplant centers face acute supply needs. Rylaze for ALL patients with documented allergic reaction to E. coli-derived asparaginase is a similar urgent-need indication. These shipments are often time-critical and Reserve Meds prioritises coordinator response.

Common cross-border destinations

The highest-frequency NPP destinations for Jazz products from US-approved inventory are the United Arab Emirates, Saudi Arabia, India, Qatar, and Turkey. Major pediatric neurology and rare-epilepsy centers in Mumbai, Bangalore, Dubai, Abu Dhabi, Riyadh, Doha, and Istanbul drive most Epidiolex referrals. Bone marrow transplant centers drive Defitelio referrals.

Manufacturer engagement posture

Reserve Meds coordinates Jazz-sourced US commercial product through DSCSA-compliant US specialty distributors for products outside the controlled-substance scope. We do not coordinate Schedule III controlled-substance shipments such as Xywav. We are not affiliated with Jazz Pharmaceuticals. For Jazz medical affairs or US commercial teams interested in cross-border NPP pathways, our BD contact is [email protected].

What Reserve Meds provides

For each non-controlled Jazz product request, Reserve Meds coordinates: prescription verification with the treating physician (pediatric neurologist for Epidiolex; hematologist or transplant physician for Defitelio and Rylaze; oncologist for Zepzelca); diagnostic documentation review where required; DSCSA serialized chain-of-custody from Jazz through licensed US wholesalers to the named patient; cold-chain shipping where required, with temperature data-loggers; ambient shipping with appropriate packaging for oral products; destination-country regulatory documentation for Ministry of Health named-patient approvals and customs clearance; and a dedicated coordinator from prescription to delivery.

Clinical governance and prescription review

Every prescription for a product on this page is reviewed by a US-licensed pharmacist before dispensing. Reserve Meds does not substitute generic equivalents for branded specialty products without an explicit prescriber instruction, and we do not dispense any product whose chain-of-custody we cannot serialize back to the FDA-authorised manufacturer or its licensed wholesale partner. Our clinical review confirms indication-on-label appropriateness based on the documentation submitted by the treating physician, identifies any standard drug-drug interaction or contraindication concerns, and confirms that the requested dose, dosing schedule, and dosage form match the prescription. Where the prescription is unclear or where the indication on the prescription is off-label, our pharmacist contacts the prescriber directly. We do not provide medical advice to patients beyond drug-information counseling at dispensing.

Supply chain integrity

Supply integrity is the foundation of Reserve Meds operations. Every shipment carries a serialized DSCSA pedigree document confirming the chain of ownership from the FDA-registered manufacturer or its authorised distributor through a licensed US wholesale distributor to Reserve Meds and onward to the named patient. We do not source through parallel-import channels, third-country re-import, or unverified online wholesale markets. Cold-chain shipments are packed in qualified shippers with temperature data-loggers reading and logging temperature throughout the journey; data-logger reads are reviewed on arrival, and any out-of-specification excursion triggers our quality-hold protocol. For frozen products such as gene therapies and certain antibody-drug conjugates, we use validated frozen-shipper systems with dry-ice replenishment as required.

Destination-country regulatory pathways

Cross-border named patient access operates under jurisdiction-specific regulatory frameworks. In the United Arab Emirates, the Ministry of Health and Prevention (MOHAP) and Dubai Health Authority operate import-permit pathways for unregistered or restricted medicines on a named-patient basis. Saudi Arabia, Qatar, Kuwait, Bahrain, and Oman each operate analogous Ministry of Health named-patient frameworks with country-specific documentation requirements. India operates a personal-import pathway under the Drugs and Cosmetics Rules for quantities consistent with personal therapeutic use, typically up to three months supply per shipment. Turkey, Egypt, Jordan, Lebanon, and Morocco each operate distinct named-patient or import-permit pathways. Reserve Meds maintains current regulatory intelligence for each of these jurisdictions and prepares the documentation package required for each shipment.

What to expect through the coordination process

Patients beginning a request receive an initial coordinator contact within one business day of submission. The coordinator reviews the prescription, identifies the documentation required for the destination country, and provides an indicative cost range. Once required documents are uploaded - prescription, prescriber license verification, patient identification, and any indication-specific documentation such as genetic test results or biomarker reports - we issue a firm quote inclusive of product cost, packaging, shipping, regulatory documentation, and our coordination fee. Patients confirm acceptance of the firm quote before any sourcing or shipping is initiated, and Reserve Meds does not collect any deposit at intake. Once the firm quote is accepted and payment is received, the coordinator initiates sourcing through our licensed wholesale partners and prepares the destination-country regulatory package. Typical end-to-end timing from accepted quote to delivery is two to four weeks for ambient-shipped products and three to five weeks for cold-chain shipments, with variability driven by destination-country customs and regulatory turnaround times.

Not affiliated with the manufacturer

Reserve Meds is an independent operator of named patient program coordination. We are not a subsidiary, affiliate, authorised distributor, or licensed representative of any pharmaceutical manufacturer, and no statement on this page should be read as a partnership, endorsement, or representation by the named manufacturer. Trade names and product references on this page are used for informational purposes to identify the FDA-approved products that Reserve Meds coordinates through US specialty wholesale channels on behalf of named individual patients.

Privacy and data handling

Patient data submitted to Reserve Meds is handled under our HIPAA-aligned privacy policy and our destination-country data protection commitments. We minimise data collection to what is necessary for prescription verification, regulatory documentation, and shipping logistics. Patient identifiable information is shared with US wholesalers, destination-country regulatory authorities, and shipping carriers only as required to complete the coordination, and is not used for any marketing purpose.

Next step for patients

Patients or caregivers with a treating-physician prescription for a Jazz product (excluding Schedule III controlled substances) can begin a request now. Start a request ›

Next step for Jazz teams

Jazz Pharmaceuticals medical affairs or commercial teams interested in cross-border NPP coordination for non-US territories can reach our BD team at [email protected].

Reserved for you.